Skip to Main Content
David Diamond, Ph.D.

David Diamond is a registered patent agent with significant experience in molecular biology, immunology, virology, oncology, and diabetes. He works with attorneys and clients in the creation of patents and global patent portfolios in varied technologies, especially biologics, including antibodies and cellular therapies, and small molecule drugs. David also lends his expertise to patent landscape and freedom-to-operate analyses.

Prior to joining K&L Gates, David headed the IP function for a biotech company as it developed from research to commercial stage. In that role he oversaw and worked with multiple outside counsel and internal staff on patent and trademark activities related to biologics, pharmaceuticals, medical devices, and industrial machinery. He was deeply engaged in patent preparation and prosecution, coordination of patent and regulatory strategy, freedom-to-operate analyses, and due diligence activities. He has broad experience in Biotech; he founded, staffed, and equipped industrial departments contributing to research, development, and regulatory affairs.

At MannKind Corporation David built a multi-faceted patent portfolio centered on their lead product, AFREZZA® (insulin human) Inhalation Powder, with laddered patent terms stretching out beyond 2030. At FDA approval in 2014, AFREZZA had 30 Orange Book listed patents and 40 patents listed on its virtual patent marking web page.

  • American Association for the Advancement of Science
  • American Association of Immunologists
  • American Society for Microbiology
  • The State Bar of California 41st Annual IP Institute, Panelist - Global Patents: Best Practices for Building and Maintaining Your International Patent Portfolio, November 2016
  • Consero Global IP Management Forum, Panelist – CAFC Year in Review, June 2016
  • The IP Strategy Summit: Orange County, Panelist - When To Trade Secret & Managing the Process, June 2016
  • Advanced Summit on Life Sciences Patents, American Conference Institute, Panelist – Method Claims: Understanding the Impact of Akamai on Direct and Divided Infringement, February 2016
  • Advanced Summit on Life Sciences Patents, American Conference Institute, Panelist – Strategically Executing a Cohesive International Life Sciences Patent Strategy for Established and Emerging Markets, January 2015
  • The IP Strategy Summit: Orange County, Panelist – Due Diligence & Portfolio Evaluation, November 2014

Articles

  • Emini, E.A.,  J. Leibowitz,  D.C. Diamond,  J. Bonin and  E. Wimmer.  Recombinants of Mahoney and Sabin Strain Poliovirus Type 1: Analysis of in vitro  Phenotypic Markers and Evidence that Resistance to Guanidine Maps to the Nonstructural Proteins.  Virology 137: 74-85, (1984).
  • Diamond, D.C.,  B.A. Jameson,  J. Bonin,  M. Kohara,  S. Abe,  H. Itoh,  T. Komatsu,  M. Arita,  A.D.M.E. Osterhaus,  R. Crainic,  A. Nomoto, and  E. Wimmer.   Antigenic Variation and Resistance to Neutralization in Poliovirus, Type 1.  Science 229:1090-1094, (1985).
  • Blondel, B.,  R. Crainic,  O. Fichot,  G. Dufraisse,  A. Candrea,  D.C. Diamond,  M. Girard,  and  F. Horaud.   Mutations Conferring Resistance to Neutralization With Monoclonal Antibodies in Type 1 Poliovirus can be Located Outside or Inside the Antibody Binding Site.  Journal of Virology  57:81-89, (1986).
  • Pincus, S.E.,  D.C. Diamond,  E.A. Emini,  and  E. Wimmer.   Guanidine Selected Mutants of Poliovirus:  Mapping of Point Mutations to Polypeptide 2C.  Journal of Virology 57:638-646, (1986).
  • Diamond, D.C.,  E. Wimmer,  K. von der Helm,  and  F. Deinhardt.   The Genomic Map of Hepatitis A Virus: An Alternate Analysis.  Microbial Pathogenesis 1:217-219, (1986).
  • Petrarca, M.A.,  C.S. Reiss,  D.C. Diamond,  J. Boni,  S.J. Burakoff,  and  D.V. Faller.     T Cell Hybridomas Define the Class II MHC-restricted Response to Vesicular Stomatitis Virus Infection.  Microbial Pathogenesis 5:319-332, (1988).
  • Diamond, D.C.,  B.P. Sleckman,  T. Gregory,  L.A. Lasky,  J.L. Greenstein,  and  S.J. Burakoff.  Inhibition of CD4+ T cell Function by the HIV Envelope Protein, gp120.  Journal of Immunology 141:3715-3717, (1988).
  • Diamond, D.C., R. Finberg, S. Chaudhuri, B.P. Sleckman, and S.J. Burakoff.  HIV Infection is Efficiently Mediated by a Glycophospholipid-anchored form of CD4.  Proc. Natl. Acad. Sci. USA. 87:5001-5005, (1990).
  • Finberg, R.*, D.C. Diamond*, D.B. Mitchell, Y. Rosenstein, G. Soman, T.C. Norman, S.L. Schreiber, and S.J. Burakoff.  Prevention of HIV-1 Infection and Preservation of CD4 Function by the Binding of CPFs to gp120.  Science 249:287-291, (1990).
    *Equal  contributors.
  • W.L. Marshall, D.C. Diamond, M.M. Kowalski, and R.L. Finberg.  High Level of Surface CD4 Prevents Stable Human Immunodeficiency Virus Infection of  T Cell Transfectants.  Journal of Virology 66:5492-5499, (1992).
  • Diamond, D.C., O. Fagoaga, S. Nehlsen-Cannarella, L.L. Bailey, and A. A. Szalay.  Sequence Comparison of Baboon ABO Histo-Blood Group Alleles: Lesions Found in O Alleles differ between Human and Baboon. Blood Cells, Molecules, and Diseases 23:242-251,(1997).
  • Best, R.G., D.C. Diamond, E. Crawford, F.S. Grass, C. Janish, T.L. Lear, D. Soenksen,  A. A. Szalay, and C.M. Moore.  Baboon/Human Homologies by Spectral Karyotyping (SKY): A Visual Comparison. Cytogenet Cell Genet 82(1-2):83-94, (1998)
  • Diamond, D.C., K. Illes, L.L. Bailey and A. A. Szalay.  Genotyping of the ABO Histo-Blood Group Locus in Baboons by Two Color Fluorescence SSCP. BioTechniques, 27:1054-1062, (1999).
  • Fatyol, K., K. Illes, D.C. Diamond, C. Janish and A.A. Szalay. Mer22-Related Sequence Elements from Pericentric Repetitive DNA Families in Primates.  Molec. Gen. Genetics 262:931-939, (2000).
  • Smith, K.A., V.L.Tam, R.M. Wong, R.R. Pagarigan, B.L. Meisenburg, D.K. Joea, X. Liu, C. Sanders, D. Diamond, T.M. Kundig, Z. Qiu, and A. Bot. Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides. Vaccine 27:2603-2615, (2009).
  • Ribas, A., J.S. Weber, B. Chmielowski1, B Comin-Anduix, D. Lu, M. Douek, N. Ragavendra, S. Raman, E Seja, D. Rosario, S. Miles, D.C. Diamond, Z. Qiu, M. Obrocea, and A. Bot. Intra-Lymph Node Prime-Boost Vaccination Against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial. Clin. Cancer Res. 17(9):2987-96, (2011).
  • Weber, J.S., N.J. Vogelzang, M.S. Ernstoff, O.B. Goodman, L.D. Cranmer, J.L. Marshall, S. Miles, D. Rosario, D.C. Diamond, Z. Qiu, M. Obrocea, and A. Bot. A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients with Advanced Solid Tumors. J. Immunother. 34(7):556-567, (2011).

Proceedings, Reviews, and Book Chapters:

  • Bonin, J.,  B.A. Jameson,  E.A. Emini,  D.C. Diamond  and  E. Wimmer.  Synthetic Peptides as Potential Vaccines Against Picornaviral Disease.  In:  "Microbiology - 1985"  (ed. D. Schlessinger)  ASM Press,  Washington, D.C.,  pp.255-261, (1985).
  • Diamond, D.C.,  R. Hanecak,  B.L. Semler,  B.A. Jameson,  J. Bonin,  and  E. Wimmer.   Structure, Proteolytic Processing, and Neutralization Antigenic Sites of Poliovirus.   In:  "35th Mosbach Colloquium: The Impact of Gene Transfer Techniques in Eukaryotic Cell Biology"  (eds.  Shell and Starlinger),  Springer-Verlag, Heidelberg,  pp.193-201, (1985).
  • Diamond, D.C.,  B.A. Jameson,  E.A. Emini,  and  E. Wimmer.  Antibody Resistant Variants of Poliovirus Type 1.   In:  "Vaccines 85"  (eds. R.A. Lerner,  R.M. Chanock, and F. Brown),  Cold Spring Harbor Press,  pp.241-247, (1985).
  • Wimmer, E.,  J. Bonin,  R. Crainic,  D. Diamond,  B. Jameson,  M. Murray,  and A. Nomoto.  Neutralization Antigenic Sites, Antibody Binding and Peptide Induction of Neutralizing antibodies of Poliovirus.  In:  "Current Communications in Molecular Biology: The Immune Recognition of Protein Antigens"  (eds. W.G. Laver and G.M. Air),  Cold Spring Harbor Press,  pp.105-112,  (1985).
  • Jameson, B.A.,  D.C. Diamond,  R. Crainic,  A. Nomoto,  and  E. Wimmer.  Characterization of Poliovirus Antibody-Dependent Neutralization.   In:  "Synthetic Peptides in Biology and Medicine"  (eds. K. Alitalo, P. Partanen, and A. Vaheri),  Elsevier Science Publishers,  pp.145-155, (1985).
  • Wimmer, E.,  E.A. Emini,  and D.C. Diamond.   Mapping of Neutralization Domains in Viruses.   In:  "Concepts in Viral Pathogenesis II"  (eds. A.L. Notkins and M.B.A. Oldstone),  Springer-Verlag, New York,  pp.159-173, (1986).
  • Diamond, D.C.,  E. Wimmer,  and E.A. Emini.   Potential Synthetic Peptide Vaccines for Enteroviruses.   In:  "Synthetic Vaccines" (ed. R. Arnon),  CRC Press,  pp.79-91,  (1987).
  • Diamond, D.C.,  M. R. Bowman,  S.L. Schreiber,  and S.J. Burakoff.  CD4: Function, Structure, and its Interactions with the HIV-1 Envelope Protein, gp120.  In: "Viruses that Affect the Immune System" (ed. H. Fan),  ASM Press, Washington, D.C., pp.93-102, (1991).
  • Silberman, S.L.,  S.J. Goldman, D.B. Mitchell, A.T. Tong, Y. Rosenstein, D.C. Diamond, R.W. Finberg, S.L. Schreiber, and S.J. Burakoff.  The Interaction of CD4 with HIV-1 gp120.  In: Seminars in IMMUNOLOGY, W.B. Saunders Company, vol. 3, pp.187-192, (1991).
  • Diamond, D.C., K. Illes, L.L. Bailey and A. A. Szalay. Genotyping of the ABO Histo-Blood Group Locus in Baboons by Two Color Fluorescence SSCP. In:"Polymorphism Detection and Analysis Techniques" BioTechniques Update Series (eds. John D. Burczak and Dr. Elaine R. Mardis). (2000).
  • Diamond, D.C. and K. Illes, Application of Two Color Fluorescence SSCP to Single Cell Genotyping of a Single Copy Gene. As an update to 10 above. (2000).
  • Z. Qiu , D.C. Diamond , K.A. Smith , D. Rosario , S. Miles , M. Obrocea , T.M. Kundig, and A. Bot, Antigen-targeted, synthetic vaccines for metastatic cancer. In: “Cancer Vaccines: From Research to Clinical Practice” (eds. A. Bot, M. Obrocea, F. Marincola) (2011).
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel